Novo Nordisk stock price forecast: $47.46 resistance as NVO surges 5.97%

Traders Union
All News
Financial News
Novo Nordisk jumps 5.97% on UK approval

Highlights

Novo Nordisk secured UK approval for its first oral Wegovy pill, immediately expanding market access and anticipated demand for weight loss treatment.
Positive late-stage CagriSema clinical results and early demand for oral Wegovy support strong commercial momentum, while recent cybersecurity issues have not affected core operations.
NVO/USD demonstrates robust bullish momentum with strong buyer dominance, immediate support at 44.48, and a projected trading range of $44.12–$47.46 for the coming days.

UK approval and clinical data boost sentiment despite cybersecurity breach

Novo Nordisk secured approval from the UK's Medicines and Healthcare products Regulatory Agency for its first oral Wegovy pill targeting weight loss, a regulatory milestone that immediately broadens its market access and is expected to drive demand, according to Blockonomi. Additional momentum has come from the release of positive late-stage clinical data for CagriSema and reported early demand for the oral Wegovy formulation, as highlighted by Quiverquant. Although the company also disclosed a prolonged cybersecurity breach by the FulcrumSec group, Cybersecurity Insiders reported that core business operations remain unaffected, which has minimized any negative impact on sentiment.

Bullish momentum and overbought signals amid technical breakout risk

NVO trades above the MA-20 ($44.36) and MA-50 ($44.07), while remaining below the MA-200 ($48.1). The Ichimoku Kijun serves as immediate support at $44.48. Intraday price action reached $45.79, with high volatility and a 0.8 gap, approaching the session’s high. Technical momentum is strong: MACD and ADX signal strength, RSI is at 67.84, both CCI and Stoch RSI are in buy or overbought territory, with BBP also flagged as overbought, and the Awesome Oscillator confirms the bullish tilt. No significant divergences are currently observed across key oscillator and momentum indicators.

Upside probability strengthens as consolidation persists within volatility band

Looking ahead to the short term, NVO is projected to trade within a volatility band of $44.12 to $47.46. The probability of a move higher is strong at 78%, with only a 22% likelihood of downside. The baseline scenario sees prices consolidating between immediate support at $44.48 and resistance near $47.46. A sustained breakout above resistance could extend gains toward the range’s upper limit, while a breach of support may trigger a move back toward the lower end.

Viktoras Karapetjanc, expert at Traders Union, sees Novo Nordisk’s momentum as driven by strong regulatory wins and robust clinical results. Positive UK approval for oral Wegovy and encouraging demand signals reinforce the fundamental growth story. He believes the recent cybersecurity breach has not shaken investor sentiment or business operations. Technicals confirm buyers are in control in the short term. "With both demand catalysts and technical strength aligning, I expect NVO to test higher levels soon if current support holds."

Earlier, analysts noted that Novo Nordisk's momentum in the obesity treatment market was driven by strategic regulatory wins and positive clinical pipeline developments. The latest approval of the oral Wegovy formulation and robust technical signals reinforce this bullish outlook, making a sustained breakout above $47.46 an important upside risk to monitor in the near term.

Source of Data: NVO Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.